<![CDATA[Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study ]]>

<![CDATA[This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequently observed but generally low grade, short in duration, and manageable with standard supportive care and dose modifications.

🔗 mentioned in this article

no entities indexed yet